NRC FORM 313 (10-2017) 10 CFR 30, 32, 33, 34, 35, 36, 37, 39, and 40

U.S. NUCLEAR REGULATORY COMMISSION

APPLICATION FOR MATERIALS LICENSE

APPROVED BY OMB: NO. 3150-0120 **EXPIRES: 06/30/2019**

Estimated burden per response to comply with this mandatory collection request: 4.3 hours. Submittal of the application is necessary to determine that the applicant is qualified and that adequate procedures exist to protect the public health and safety. Send comments regarding burden estimate to the Information Services Branch (T-2 F43), U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, or by e-mail to Infocollects.Resource@nrc.gov, and to the Desk Officer, Office of Information and Regulatory Affairs, NEOB-10202, (3150-0120), Office of Management and Budget, Washington, DC 20503. If a means used to impose an information collection does not display a currently valid OMB control number, the NRC may not conduct or sponsor, and a person is not required to respond to, the information collection.

INSTRUCTIONS: SEE THE CURRENT VOLUMES OF THE NUREG-1556 TECHNICAL REPORT SERIES ("CONSOLIDATED GUIDANCE ABOUT MATERIALS LICENSES") FOR DETAILED INSTRUCTIONS FOR COMPLETING THIS FORM: http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/. SEND TWO COPIES OF THE COMPLETED APPLICATION TO THE NRC OFFICE SPECIFIED BELOW.

APPLICATION FOR DISTRIBUTION OF EXEMPT PRODUCTS FILE APPLICATIONS WITH:

MATERIALS SAFETY LICENSING BRANCH
DIVISION OF MATERIAL SAFETY, STATE, TRIBAL AND RULEMAKING PROGRAMS
OFFICE OF NUCLEAR MATERIALS SAFETY AND SAFEGUARDS
U.S. NUCLEAR REGULATORY COMMISSION
WASHINGTON, DC 20555-0001

ALL OTHER PERSONS FILE APPLICATIONS AS FOLLOWS:

IF YOU ARE LOCATED IN:

ALABAMA, CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, FLORIDA, GEORGIA, KENTUCKY, MAINE, MARYLAND, MASSACHUSETTS, NEW HAMPSHIRE, NEW JERSEY, NEW YORK, NORTH CAROLINA, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, VERMONT, VIRGINIA, VIRGIN ISLANDS, OR WEST VIRGINIA,

SEND APPLICATIONS TO:

LICENSING ASSISTANCE TEAM
DIVISION OF NUCLEAR MATERIALS SAFETY
U.S. NUCLEAR REGULATORY COMMISSION, REGION I
2100 RENAISSANCE BOULEVARD, SUITE 100
KING OF PRUSSIA, PA 19406-2713

IF YOU ARE LOCATED IN:

ILLINOIS, INDIANA, IOWA, MICHIGAN, MINNESOTA, MISSOURI, OHIO, OR WISCONSIN, SEND APPLICATIONS TO:

MATERIALS LICENSING BRANCH
U.S. NUCLEAR REGULATORY COMMISSION, REGION III
2443 WARRENVILLE ROAD, SUITE 210
LISLE, IL 60532-4352

IF YOU ARE LOCATED IN:

ALASKA, ARIZONA, ARKANSAS, CALIFORNIA, COLORADO, HAWAII, IDAHO, KANSAS, LOUISIANA, MISSISSIPPI, MONTANA, NEBRASKA, NEVADA, NEW MEXICO, NORTH DAKOTA, OKLAHOMA, OREGON, PACIFIC TRUST TERRITORIES, SOUTH DAKOTA, TEXAS, UTAH, WASHINGTON, OR WYOMING,

SEND APPLICATIONS TO:

NUCLEAR MATERIALS LICENSING BRANCH
U.S. NUCLEAR REGULATORY COMMISSION, REGION IV
1600 E. LAMAR BOULEVARD
ARLINGTON, TX 76011-4511

PERSONS LOCATED IN AGREEMENT STATES SEND APPLICATIONS TO THE U.S. NUCLEAR REGULATORY COMMISSION ONLY IF THEY WISH TO POSSESS AND USE LICENSED MATERIAL IN STATES SUBJECT TO U.S. NUCLEAR REGULATORY COMMISSION JURISDICTIONS.

1. THIS IS AN APPLICATION FOR *(Check appropriate item)*

- [ ] A. NEW LICENSE
- [x] B. AMENDMENT TO LICENSE NUMBER 13-32726-01MD
- [ ] C. RENEWAL OF LICENSE NUMBER

2. NAME AND MAILING ADDRESS OF APPLICANT *(Include zip code)*

John Zehner
17490 Dugdale Dr.
South Bend, IN 46635

3. ADDRESS WHERE LICENSED MATERIALS WILL BE USED OR POSSESSED

John Zehner
17490 Dugdale Dr.
South Bend, IN 46635

4. NAME OF PERSON TO BE CONTACTED ABOUT THIS APPLICATION

John Zenher

BUSINESS TELEPHONE NUMBER	BUSINESS CELLULAR TELEPHONE NUMBER
	(317) 459-8315

BUSINESS E-MAIL ADDRESS
jzehner@spectronrx.com

SUBMIT ITEMS 5 THROUGH 11 ON 8-1/2 X 11" PAPER. THE TYPE AND SCOPE OF INFORMATION TO BE PROVIDED IS DESCRIBED IN THE LICENSE APPLICATION GUIDE.

5. RADIOACTIVE MATERIAL
   a. Element and mass number; b. chemical and/or physical form; and c. maximum amount which will be possessed at any one time.

6. PURPOSE(S) FOR WHICH LICENSED MATERIAL WILL BE USED.

7. INDIVIDUAL(S) RESPONSIBLE FOR RADIATION SAFETY PROGRAM AND THEIR TRAINING AND EXPERIENCE.

8. TRAINING FOR INDIVIDUALS WORKING IN OR FREQUENTING RESTRICTED AREAS.

9. FACILITIES AND EQUIPMENT.

10. RADIATION SAFETY PROGRAM.

11. WASTE MANAGEMENT.

12. LICENSE FEES (Fees required only for new applications, with few exceptions*)
(See 10 CFR 170 and Section 170.31)
***Amendments/Renewals that increase the scope of the existing license to a new or higher fee category will require a fee.**

FEE CATEGORY: N/A AMOUNT ENCLOSED $: 0.00

PER THE DEBT COLLECTION IMPROVEMENT ACT OF 1996 (PUBLIC LAW 104-134), YOU ARE REQUIRED TO PROVIDE YOUR TAXPAYER IDENTIFICATION NUMBER. PROVIDE THIS INFORMATION BY COMPLETING NRC FORM 531: https://www.nrc.gov/reading-rm/doc-collections/forms/nrc531info.html.

13. CERTIFICATION. *(Must be completed by applicant) THE APPLICANT UNDERSTANDS THAT ALL STATEMENTS AND REPRESENTATIONS MADE IN THIS APPLICATION ARE BINDING UPON THE APPLICANT.*

THE APPLICANT AND ANY OFFICIAL EXECUTING THIS CERTIFICATION ON BEHALF OF THE APPLICANT, NAMED IN ITEM 2, CERTIFY THAT THIS APPLICATION IS PREPARED IN CONFORMITY WITH TITLE 10, CODE OF FEDERAL REGULATIONS, PARTS 30, 32, 33, 34, 35, 36, 37, 39, AND 40, AND THAT ALL INFORMATION CONTAINED HEREIN IS TRUE AND CORRECT TO THE BEST OF THEIR KNOWLEDGE AND BELIEF.
WARNING: 18 U.S.C. SECTION 1001 ACT OF JUNE 25, 1948 62 STAT. 749 MAKES IT A CRIMINAL OFFENSE TO MAKE A WILLFULLY FALSE STATEMENT OR REPRESENTATION TO ANY DEPARTMENT OR AGENCY OF THE UNITED STATES AS TO ANY MATTER WITHIN ITS JURISDICTION.

CERTIFYING OFFICER -- TYPED/PRINTED NAME AND TITLE	SIGNATURE	DATE
John A. Zehner, CEO NukeMed on behalf of Greg Hiatt		7/9/19

FOR NRC USE ONLY

TYPE OF FEE	FEE LOG	FEE CATEGORY	AMOUNT RECEIVED	CHECK NUMBER	COMMENTS
			$		
APPROVED BY				DATE	

NRC FORM 313 (10-2017)

RECEIVED JUL 17 2019

SpectronRx

July 9, 2019

Sara A. Forster, M.S.
Health Physicist
Materials Licensing Branch

RE: License #: 13-32726-01MD

Dear Ms. Forster:

Thank you for your time on June 17, 2019. As per our conversation, we are contemplating the acquisition of Spectron mrc from Greg Hiatt. We understand that we need to provide advance notice for this change of control. We will separate the request for transfer of control verses our response to your letter dated December 31, 2018. In this letter, we are requesting a change of RSO and responding to your letter dated December 31, 2018. Another letter requesting the transfer of control will follow.

Please see the Power of Attorney (see Attachment 1) from Greg Hiatt, R.Ph. as the current RSO of Spectron mrc, LLC, authorizing John A. Zehner, Chief Executive Officer of NukeMed, Inc., dba SpectronRx to make the following changes to License # 13-32726-01MD. Greg Hiatt, R.Ph. is also the primary owner of Spectron mrc, LLC.

We are requesting that we replace Greg Hiatt as RSO with John A. Zehner on License 13-32726-01MD. Mr. Zehner is a currently an Authorized User on the license and maintains his registration as an Indiana Pharmacist (see Attachment 2). Mr. Zehner was previously RSO on the Zevacor Molecular License, #13-35179-02. Mr. Hiatt will remain as an authorized user.

In response to your letter Dated December 31, 2018, and as discussed in our conversation on June 17, 2019, we intend to remain a Nuclear Pharmacy. The Iodine limit increase was requested to perform Iodine capsule compounding under a physician's prescription, as well as, radioiodination of various molecular entities for specific patient use, dispensed under a physician's prescription and/or under an FDA approved IND.

Our request for 8.5 Curies results from the need of the size of the therapeutic doses we will be dispensing, and waste held for decay. Our radioiodination compounding has a batch size of up to 5 Curies of Iodine 131. We anticipate sending significantly all the Iodine product to patients with each batch but do expect some waste to be held for decay either via the vendor Iodine 131 shipping container or as needed for Quality Control of the product. Each batch can serve approximately 15 patients. We anticipate requests of up to 15 patients per week. Our request for 8.5 Curies is to address any waste that may be produced and held for decay over time plus potential weekly shipments of new Iodine 131 from a vendor. In addition, it has been made public that we are assisting Y-mAbs with its cancer therapy for children. This is an Iodine 131 product that also justifies the increased possession limit. See Attachment 3 – Press Release.

Calculation of possession limit need:

Receipt of I-131 from the vendor is anticipated to be 5 Curies. We assume worst case of 40% or 2 Curie of the I-131 to be held for decay due to waste in the vendor container, samples for Quality Control and activity not used of the product. We assume the remainder, 3 Curies, will be sent for patient use. Given

SpectronRx

we could potentially perform a batch each week, we expect to have the waste from multiple batches being held for decay in our waste. If we assume a 90 plus day waste cycle, we then expect to always have approximately 2.5 Curies of Iodine 131 in our waste. A new Iodine 131 shipment plus the waste would be approximately 7.5 Curies. We are requesting 8.5 Curies to allow for a variance in waste or a new shipment since the activity could be plus or minus 10%. Plus, we would like to have sufficient Iodine 131 on hand to address patient need for Capsule and solution compounding.

I believe we addressed bioassay, exhaust, equipment in the previous letters. Please contact us with any additional questions.

We have calculated the requirement to consider an emergency plan per 10 CFR 30.72 Schedule C, but it is our understanding our request remained below this requirement since our ratio is below 1. See Attachment 4 – 10 CFR 30.72 Schedule C Ratios.

If you have any questions, please feel free to contact John A. Zehner at JZehner@NukeMed.com or JZehner@SpectronRx.com, as well as, at my main number at 317.459.8315.

Sincerely,

John A. Zehner, R.Ph.
CEO
NukeMed, Inc. dba SpectronRx

Attachments:

1) Limited Power of Attorney
2) John Zehner Indiana Pharmacist License
3) Y-mAbs Press Release
4) 10 CFR 30.72 Schedule C Ratios

Attachment 1

LIMITED POWER OF ATTORNEY

BE IT KNOWN that Gregory S. Hiatt, RPh, as Radiation Safety Officer of Spectron mrc. LLC, located at 17940 Dugdale Drive, South Bend, IN 46635, and holder of **NRC Material License No. 13-32726-01MD (the "License")**, has made and appointed and by these presents does make and appoint John A. Zehner, Chief Executive Officer of NukeMed, Inc., dba SpectronRx, true and lawful attorney for Gregory S. Hiatt in his name, place and stead, for the following specific and limited purposes only:

To execute all documents and take all other action necessary to name a new Radiation Safety Officer as well as transfer ownership and amend any and all terms of the License.

Giving and granting said attorney, until this Limited Power Of Attorney is terminated, full power and authority to do and perform all and every act and thing whatsoever necessary to be done in and about the specific and limited premises (set out herein above) as fully, to all intents and purposes, as might or could be done if personally present, with full power of substitution and revocation, hereby ratifying and confirming all that said attorney shall lawfully do or cause to be done by virtue hereof. NukeMed, Inc., agrees to indemnify and hold harmless, Spectron mrc, LLC and Gregory S. Hiatt, RPh, for any and all liabilities or obligations, costs or expenses related to the License or all other matters that are attributable to the actions of NukeMed, Inc. or John A. Zehner.

IN WITNESS WHEREOF, Gregory S. Hiatt, RPh, has caused this Limited Power of Attorney to be executed on this 12th day of June, 2019.

Gregory S. Hiatt

Gregory S. Hiatt, RPh

ASHLEY ZUMBRUN, Notary Public, Primarily Employed in Indiana, Commission Number NP0715932, My Commission Expires 09/20/2026

STATE OF INDIANA)
COUNTY OF St Joseph)

Before me the undersigned, a Notary Public in and for said County and State, personally appeared Gregory S. Hiatt, RPh, and acknowledged the execution of this Limited Power of Attorney on this 12th day of June, 2019.

My Commission Expires:

09/20/2026

Name: Ashley Zumbrun
County of Residence: Cass
NOTARY PUBLIC

The undersigned on behalf of NukeMed,Inc, as its authorized representative, hereby agrees on behalf of NukeMed, Inc. to the hold harmless and the indemnity provisions described and contained hereinabove.

NukeMed, Inc.

By: _____
John A. Zehner, Duly Authorized Representative.

This instrument prepared by Gregory J. Cagnassola, Attorney at Law
DeFur Voran LLP, 8409 Fishers Centre Drive, Fishers, IN 46038
Telephone: (317) 585-8085

I affirm under the penalties for perjury that I have taken all reasonable care to redact each Social Security number in this document unless required by law. Gregory J. Cagnassola

Attachment 1

LIMITED POWER OF ATTORNEY

BE IT KNOWN that Gregory S. Hiatt, RPh, as Radiation Safety Officer of Spectron mrc. LLC, located at 17940 Dugdale Drive, South Bend, IN 46635, and holder of **NRC Material License No. 13-32726-02 (the "License")**, has made and appointed and by these presents does make and appoint John A. Zehner, Chief Executive Officer of NukeMed, Inc., dba SpectronRx, true and lawful attorney for Gregory S. Hiatt in his name, place and stead, for the following specific and limited purposes only:

To execute all documents and take all other action necessary to name a new Radiation Safety Officer as well as transfer ownership and amend any and all terms of the License.

Giving and granting said attorney, until this Limited Power Of Attorney is terminated, full power and authority to do and perform all and every act and thing whatsoever necessary to be done in and about the specific and limited premises (set out herein above) as fully, to all intents and purposes, as might or could be done if personally present, with full power of substitution and revocation, hereby ratifying and confirming all that said attorney shall lawfully do or cause to be done by virtue hereof. NukeMed, Inc., agrees to indemnify and hold harmless, Spectron mrc, LLC and Gregory S. Hiatt, RPh, for any and all liabilities or obligations, costs or expenses related to the License or all other matters that are attributable to the actions of NukeMed, Inc. or John A. Zehner.

IN WITNESS WHEREOF, Gregory S. Hiatt, RPh, has caused this Limited Power of Attorney to be executed on this 12th day of June, 2019.

Gregory S. Hiatt, RPh

ASHLEY ZUMBRUN,
Notary Public
Primarily Employed in Indiana
Commission Number NP0715932
My Commission Expires 09/20/2026

STATE OF INDIANA)
COUNTY OF St. Joseph)

Before me the undersigned, a Notary Public in and for said County and State, personally appeared Gregory S. Hiatt, RPh, and acknowledged the execution of this Limited Power of Attorney on this 12th day of June, 2019.

My Commission Expires:
09/20/2026

Name: Ashley Zumbrun
County of Residence: Cass
NOTARY PUBLIC

The undersigned on behalf of NukeMed,Inc, as its authorized representative, hereby agrees on behalf of NukeMed, Inc. to the hold harmless and the indemnity provisions described and contained hereinabove.

NukeMed, Inc.

By: _____
John A. Zehner, Duly Authorized Representative.

This instrument prepared by Gregory J. Cagnassola, Attorney at Law
DeFur Voran LLP, 8409 Fishers Centre Drive, Fishers, IN 46038
Telephone: (317) 585-8085

I affirm under the penalties for perjury that I have taken all reasonable care to redact each Social Security number in this document unless required by law. Gregory J. Cagnassola

State of Indiana

Demographic Information

Name: JOHN ANDREW ZEHNER

Address Information

City/State/Zip: Indianapolis IN 46236

County: Marion

License Information

Lic #: 26017457A **Profession:** Pharmacy Board **Type:** Pharmacist **Secondary:**

Status: Active **Issued:** 10/23/1991 **Expiration:** 6/30/2020

Method: Examination

Discipline Information

Related Licenses

Lic #: 60006489A **Name:** Global Isotopes, LLC. dba Zevacor Molecular

License Type: Pharmacy **License Status:** Closed Facility **Relationship:** Managing Pharmacist

Lic #: **Name:** Global Isotopes, LLC. dba Zevacor Molecular

License Type: Pharmacy **License Status:** Withdrawn Application **Relationship:** Managing Pharmacist

Documents

No Public Documents Available

Attachment 3

Y-mAbs Secures Commercial Radiolabeling Capacity

July 1, 2019

NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Company has entered a development, manufacturing and supply agreement with SpectronRx in South Bend, Indiana, to secure access to clinical and commercial scale radiolabeling capacity for omburtamab. Under the terms of the agreement, SpectronRx has agreed to establish a manufacturing unit designated for Y-mAbs within its existing facilities, at which both clinical and commercial supply of radiolabelled omburtamab can be produced.

Omburtamab is in a pivotal Phase II trial for the treatment of CNS/LM from neuroblastoma, a Phase I trial for the treatment of Diffuse Intrinsic Pontine Glioma ("DIPG"), and a Phase I for the treatment of Desmoplastic Small Round Cell Tumours ("DSRCT"). The Company expects to file a biologics license application ("BLA") for omburtamab for the treatment of CNS/LM from neuroblastoma during 2019.

"The agreement with SpectronRx is designed to secure clinical and commercial scale radiolabeling capacity for omburtamab, and to allow us to supply the US market upon potential FDA approval of omburtamab. The facility will also serve as back-up for the Company's overseas activities," stated Thomas Gad, Founder, Chairman, President and Head of Business Development and Strategy.

Dr. Claus Moller, Chief Executive Officer continued, "We see great potential in radiopharmaceuticals, and we are excited to begin our collaboration with SpectronRx. We believe SpectronRx has the necessary expertise within radiolabeling of monoclonal antibodies to be a great partner supporting our launch strategy for omburtamab."

About Y-mAbs

Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates —naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our business model and development and commercialization plans; current and future clinical and pre-clinical studies and our research and development programs; regulatory, marketing and reimbursement approvals; rate and degree of market acceptance and clinical utility as well as pricing and reimbursement levels; retaining and hiring key employees; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position and strategy; additional product candidates and technologies; collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of our cash and cash equivalents, and the need for, timing and amount of any future financing transaction; our financial performance, including our estimates regarding revenues, expenses, capital expenditure requirements; developments relating to our competitors and our industry; and other statements that are not historical facts. Words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will", "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with our financial condition and need for additional capital; risks associated with our development work; cost and success of our product development activities and clinical trials; the risks of delay or failure to receive approval of our drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of our product candidates; development of our sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for our products; the risks related to our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of our intellectual property rights; risks related to employee matters and managing growth; risks related to our common stock and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in our Form 10-K and in our other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:

Y-mAbs Therapeutics, Inc.
230 Park Avenue, Suite 3350
New York, NY 10169
USA

+1 646 885 8505

E-mail: info@ymabs.com

Source: Y-mAbs Therapeutics, Inc

Attachment 4
10 CFR 30.72 - Schedule C Ratios

Nuclide	Quantity (Ci)	Limit (Ci)	Ratio
Actinium-228	0	4,000	0
Americium 241	0	2	0
Americium-242	0	2	0
Americium-243	0	2	0
Antimony-124	0.2	4,000	0.00005
Antimony-126	0.2	6,000	3.33E-05
Barium-133	0	10,000	0
Barium-140	0.2	30,000	6.67E-06
Bismuth-207	0	5,000	0
Bismuth-210	0.2	600	0.000333
Cadmium-109	0	1,000	0
Cadmium-113	0	80	0
Calcium-45	0	20,000	0
Californium-252	0	9	0
Carbon-14 (non-carbon dioxide)	0	50,000	0
Cerium-141	0.2	10,000	0.00002
Cerium-144	0	300	0
Cesium-134	0	2,000	0
Cesium-137	0	3,000	0
Chlorine-36	0	100	0
Chromium-51	0.2	300,000	6.67E-07
Cobalt-60	0	5,000	0
Copper-64	3	200,000	0.000015
Curium-242	0	60	0
Curium-243	0	3	0
Curium-244	0	4	0
Curium-245	0	2	0
Europium-152	0	500	0
Europium-154	0	400	0
Europium-155	0	3,000	0
Germanium-68	0.2	2,000	0.0001
Gadolinium-153	0	5,000	0
Gold-198	0.2	30,000	6.67E-06
Hafnium-172	0	400	0
Hafnium-181	0.2	7,000	2.86E-05
Holmium-166m	0	100	0
Hydrogen-3	0	20,000	0
Iodine-125	0	10	0
Iodine-131	8.5	10	0.85
Indium-114m	0.2	1,000	0.0002
Iridium-192	0.2	40,000	0.000005
Iron-55	0	40,000	0
Iron-59	0.2	7,000	2.86E-05
Krypton-85	0	6,000,000	0

Attachment 4

10 CFR 30.72 - Schedule C Ratios

Lead-210	0	8	0
Manganese-56	0.2	60,000	3.33E-06
Mercury-203	0.2	10,000	0.00002
Molybdenum-99	20	30,000	0.000667
Neptunium-237	0	2	0
Nickel-63	0	20,000	0
Niobium-94	0	300	0
Phosphorus-32	0.2	100	0.002
Phosphorus-33	0.2	1,000	0.0002
Polonium-210	0	10	0
Potassium-42	0.2	9,000	2.22E-05
Promethium-145	0	4,000	0
Promethium-147	0	4,000	0
Radium-226	0	100	0
Ruthenium-106	0	200	0
Samarium-151	0	4,000	0
Scandium-46	0.2	3,000	6.67E-05
Selenium-75	0.2	10,000	0.00002
Silver-110m	0	1,000	0
Sodium-22	0	9,000	0
Sodium-24	0.2	10,000	0.00002
Strontium-89	0.2	3,000	6.67E-05
Strontium-90	0	90	0
Sulfur-35	0.2	900	0.000222
Technitium-99	0	10,000	0
Technitium-99m	20	400,000	0.00005
Tellurium-127m	0.2	5,000	0.00004
Tellurium-129m	0.2	5,000	0.00004
Terbium-160	0.2	4,000	0.00005
Thulium-170	0	4,000	0
Tin-113	1	10,000	0.0001
Tin-123	0	3,000	0
Tin-126	0	1,000	0
Titanium-44	0	100	0
Vanadium-48	0.2	7,000	2.86E-05
Xenon-133	0.2	900,000	2.22E-07
Yttrium-91	0.2	2,000	0.0001
Zinc-65	0	5,000	0
Zirconium-93	0	400	0
Zirconium-95	0.2	5,000	0.00004
Other alpha (Ac-225)	150	2,000	0.075
Other beta-gamma (Lu-177)	15000	10,000,000	0.0015
		Total	**0.9311**



Align top of FedEx Express® shipping label here.

ORIGIN ID:MZ2A (555) 555-5555
JULIET ELIZABETH HALL
13571 LAKE RIDGE LN
MCCORDSVILLE, IN 46055
UNITED STATES US

SHIP DATE: 15JUL19
ACTWGT: 0.30 LB
CAD: 6991874/SSF02002

BILL CREDIT CARD

TO SARA A FORSTER – HLTH PHY. LIC
U.S. NUCLEAR REGULATORY COM. REG
2443 WARRENVILLE RD
STE 210
LISLE IL 60532
(630) 827-0871

INV:
PO:
REF

RECEIVED JUL 17 2019

FedEx Express

REL# 3785346

TRK# 0201 7884 6121 3841

THU – 18 JUL 4:30P
EXPRESS SAVER

SH ENLA

60532
IL-US ORD